t(2;11)(p21;q23) KMT2A/?

Jean-Loup Huret

Medical Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France. jean-loup.huret@chu-poitiers.fr

Published in Atlas Database: August 2016
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0211ID1109.html
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/66248/08-2016-t0211ID1109.pdf
DOI: 10.4267/2042/66248

This article is an update of :
Fleischman EW. t(2;11)(p21;q23). Atlas Genet Cytogenet Oncol Haematol 2000;4(1)

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract
Review on t(2;11)(p21;q23) with MLL (KMT2A) involvement, with data on clinics, and the genes involved.

Keywords
Chromosome 2; chromosome 11; MLL; KMT2A; acute myeloid leukemia; acute lymphoblastic leukemia

Clinics and pathology

Disease
Myelodysplastic syndromes: (MDS), acute myeloid leukemia: (AML) and acute lymphoblastic leukemia (ALL).

Phenotype/cell stem origin
Although at least 43 cases of t(2;11)(p21;q23) have been described in hematological malignancies (19 MDS, 21 AML, 2 acute lymphocytic leukemia (ALL) and 1 chronic lymphocytic leukemia: (CLL) (Mitelman et al., 2016)., The implication of MLL was ascertained in only 5 cases (Thirman et al., 1993; Finke et al., 1994; Fleischman et al., 1999; Kim et al., 2002; Meyer et al., 2006), a case with a hidden involvement of AFF3 (2q11) being discarded (Hiwatari et al., 2003), while thirty two case of t(2;11)(p21;q23) without MLL rearrangement are available (review in Ruano and Shetty, 2016). There were a case of refractory anemia with excess of blasts: (RAEB) evolving towards an AML, a M0-AML: evolving towards a M4-AML, a M5a-AML, and two ALLs.

![Image of chromosome bands] 

(t(2;11)(p21;q23) G- banding (left) - Courtesy Eric Crawford, and R- banding (Editor)
**Epidemiology**

Sex ration was 3M/1F. Patients were aged 8 months, 58, 58, and 61 years (Thirman et al., 1993; Finke et al., 1994; Fleischman et al., 1999; Kim et al., 2002).

**Clinics**

variable

**Cytogenetics**

**Additional anomalies**

The t(2;11)(p21;q23) was the sole abnormality in 3 cases, and was accompanied with , del(5q) in one case. It is of note that deletions of 5q usually are not seen in cases with MLL-associated translocations.

**Genes involved and proteins**

Note

the gene involved in 2p in unknown

**KMT2A** *(myeloid/lymphoid or mixed lineage leukemia)*

**Location**

11q23.3

**DNA/RNA**

37 exons, spanning about 120 kb; 13-15 mRNA

**Protein**

3969 amino acids, 431 kDa; Transcriptional regulatory factor. MLL is known to be associated with more than 30 proteins, including the core components of the SWI/SNF chromatin remodeling complex and the transcription complex TFIIID. MLL binds promoters of HOX genes through acetylation and methylation of histones. MLL is a major regulator of hematopoiesis and embryonic development, through regulation of HOX genes expression regulation (HOXA9 in particular).

**Result of the chromosomal anomaly**

**Hybrid gene**

**Description**

unknown

**Fusion protein**

**Description**

unknown

**References**

Mitelman F, Johansson B and Mertens F (Eds.). Mitelman Database of Chromosome aberrations and Gene fusions in Cancer (2016).


Ruano, AL, Shetty, S. t(2;11)(p21;q23) without KMT2A (MLL) rearrangement Atlas Genet Cytogenet Oncol Haematol http://atlasgeneticsoncology.org/Anomalies/t0211p21q23I D1333.html


This article should be referenced as such: